



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ



# شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



شبكة المعلومات الجامعية

# جامعة عين شمس

التوثيق الالكتروني والميكروفيلم

## قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
على هذه الأفلام قد أعدت دون أية تغيرات



## يجب أن

تحفظ هذه الأفلام بعيدا عن الغبار

في درجة حرارة من ١٥-٢٥ مئوية ورطوبة نسبية من ٢٠-٤٠%

To be Kept away from Dust in Dry Cool place of  
15-25- c and relative humidity 20-40%

# بعض الوثائق الأصلية تالفة

# بالرسالة صفحات لم ترد بالاصل

# **Study of Fungal Infections in Pediatric Oncology Patients**

*Thesis*  
*Submitted for partial fulfillment of Master Degree*  
*In Pediatrics*

*By*  
**Asmaa Abdel Sameea Mahmoud**  
M.B., B.Ch., Menoufyia University

*Supervised by*  
**Prof. Dr. Farida Hussein El Rashedi**  
Professor of Pediatrics,  
Faculty of Medicine, Menoufyia University

F.H.

**Prof. Dr. Fady Mohammed El Gendy**  
Professor of Pediatrics,  
Faculty of Medicine, Menoufyia University

FADY

**Dr. Bothina Abdel Aziz Qora**  
Assistant Professor of Microbiology,  
Faculty of Medicine, Menoufyia University

Bothina

**Dr. Ahmed Anwar Khatab**  
Lecturer of Pediatrics,  
Faculty of Medicine, Menoufyia University

Ah-Kt.

**Faculty of Medicine**  
**Menoufyia University**  
**2007**

✓-1  
29

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

﴿قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا

مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ

الْحَكِيمُ﴾

سورة البقرة  
آية رقم: (٣٢)

## **ACKNOWLEDGEMENT**

***\*First and foremost, thanks to ALLAH,  
The most beneficent and most merciful\****

I would like to express my deepest gratitude and sincere thanks to ***Prof. Dr. Farida Hussein El Rashedi***, Professor of Pediatrics, Faculty of Medicine, Menoufyia University, for her instructive supervision, continuous guidance, valuable instructions, precious and continuous encouragement. I have a great deal and gained valuable experience.

I would like to express my deepest gratitude and profound thanks to ***Prof. Dr. Fady Mohammed El Gendy***, Professor of Pediatrics, Faculty of Medicine, Menoufyia University for his expert guidance, valuable suggestions, and excellent supervision. I felt a great honor to work under his supervision.

I owe much to ***Dr. Bothina Abdel Aziz Qora***, assistant Prof. Of Microbiology, Faculty of Medicine, Menoufyia University, for her tremendous assistance, continuous guidance, valuable suggestions, kind instructions and support all over the work.

Deep thanks to ***Dr. Ahmed Anwar Khatab***, Lecturer of Pediatrics, Faculty of Medicine, Menoufyia University, for his tremendous efforts in the close reading of the work, valuable suggestions, kind instructions and excellent supervision.



# LIST OF CONTENTS

	<b>Page</b>
LIST OF ABBREVIATIONS	I
LIST OF TABLES	ii
LIST OF FIGURES	iii
INTRODUCTION	1
AIM OF THE WORK	3
REVIEW OF THE LITERATURE	4
❖ Child-hood cancer.	
❖ Febrile neutropenia in pediatric oncology patients.	
❖ Infection in febrile neutropenic cancer patients.	
❖ Evaluation of the febrile neutropenic cancer patients.	
❖ Management of febrile neutropenic cancer patients.	
❖ Prevention of infection in cancer patients.	
❖ Infectious complications and treatment.	
PATIENTS & METHODS	89
RESULTS	96
DISCUSSION	120
SUMMARY	129
CONCLUSIONS	132
RECOMMENDATIONS	133
REFERENCES	134
ARABIC SUMMARY	154

# LIST OF ABBREVIATIONS

ALL	Acute lymphoblastic leukemia
AMC	Absolute monocytic count
AML	Acute myeloid leukemia
ANC	Absolute neutrophil count
BAL	Bronchoalveolar lavage
CD	Cluster differentiation
CT	Computed tomography
DNA	Deoxyribose nucleic acid
EBV	Epstein-Barr virus
ECG	Electrocardiogram
e.g.	Exempli gratia (Latin= for example)
ESR	Erythrocyte sedimentation rate
FAB	French-American-British
FDA	Food and drug Administration
FN	Febrile neutropenia
FUO	Fever of unknown origin
G-CSF	Granulocyte-colony stimulating factor
GM-CSF	Granulocyte-macrophage colony stimulating factor
HD	Hodgkin disease
HIV	Human immunodeficiency virus
IgM	Immunoglobulin M
I.V.	Intravenous
NAC	Non-albicans Candida
NHL	Non-Hodgkin's Lymphoma
PCR	Polymerase chain reaction
PMN	Polymorphonuclear neutrophil
SNCCCL	Small non-cleaved cell lymphoma
T.d.T.	Terminal deoxynucleotide transferase

# LIST OF TABLES

		Page
<b>Tables of Review</b>		
<b>I</b>	Clinical and Laboratory Features at Diagnosis in Children with ALL	8
<b>II</b>	FAB Classification of Acute Lymphoblastic Leukemia	11
<b>III</b>	Treatment options based on risk and site of therapy	53
<b>Tables of results</b>		
<b>1</b>	Distribution of studied patients according to age and sex.	96
<b>2</b>	Type of cancers of studied patients.	97
<b>3</b>	Immunophenotype of cancers of studied patients.	98
<b>4</b>	Presenting symptoms of studied febrile neutropenic oncology patients.	99
<b>5</b>	Prevalence of fungal and bacterial infections among febrile neutropenic oncology patients.	101
<b>6</b>	Prevalence of fungal infections among different types of cancer.	102
<b>7</b>	Results of fungal blood culture of studied febrile neutropenic oncology patients by type of cancer.	103
<b>8</b>	Prevalence of bacterial infections among different types of cancer.	105
<b>9</b>	Results of bacterial blood culture of studied febrile neutropenic oncology patients by type of cancer.	106
<b>10</b>	Antifungal culture sensitivity results.	108
<b>11</b>	Relationship between duration of neutropenia in studied patients and occurrence of fungal infection.	109
<b>12</b>	Comparison between patients with fungal infection versus patients without infection and some laboratory data.	110
<b>13</b>	Relationship between Immunophenotype of cancer and fungal infections among febrile neutropenic patients.	111
<b>14</b>	Relationship between stage of treatment of cancer and fungal infections among febrile neutropenic patients.	112
<b>15</b>	Relationship between type of drugs used in treatment of cancer and fungal infections among febrile neutropenic patients.	113
<b>16</b>	Outcome of studied patients in relation to fungal infection	115

# **LIST OF FIGURES**

		<b>Page</b>
<b>1</b>	Type of cancers of studied patients.	97
<b>2</b>	Presenting symptoms of studied febrile neutropenic oncology patients.	100
<b>3</b>	Prevalence of fungal and bacterial infections among febrile neutropenic oncology patients.	101
<b>4</b>	Prevalence of fungal infections among different types of cancer.	102
<b>5</b>	Results of fungal blood culture of studied febrile neutropenic oncology patients by type of cancer.	104
<b>6</b>	Prevalence of bacterial infections among different types of cancer.	105
<b>7</b>	Results of bacterial blood culture of studied febrile neutropenic oncology patients by type of cancer.	107
<b>8</b>	Antifungal culture sensitivity results.	108
<b>9</b>	Relationship between duration of neutropenia in studied patients and occurrence of fungal infection.	109
<b>10</b>	Comparison between patients with fungal infection versus patients without infection and laboratory data.	110
<b>11</b>	Relationship between stage of treatment of cancer and fungal infections among febrile neutropenic patients.	112
<b>12</b>	Relationship between type of drugs used in treatment of cancer and fungal infections among febrile neutropenic patients.	114
<b>13</b>	Outcome of studied patients in relation to fungal infection.	115

# INTRODUCTION

# INTRODUCTION

Infections are common and potentially serious complications of cancer treatment. The most important risk factor for infection is an absolute neutrophil count less than  $500 / \text{mm}^3$ , and its duration (*Oude Nijhuis et al., 2005*).

In the early 1970s, the introduction of empirical use of intravenous broad-spectrum antibiotics for febrile neutropenic patients reduced infection-related mortality significantly. Until recently, routine hospitalization for administration of intravenous broad-spectrum antibiotics is still standard care and the paradigm in most hospitals (*Oude Nijhuis et al., 2005*).

Oncology patients overall had a decreased mortality rate over time, likely attributable to advances in medical therapy in treating a variety of neoplasms. However, patients who acquired fungal infections did not experience a similar improvement in mortality. Although fungal infections themselves were not usually fatal events, they were associated with a 60% mortality rate in cancer patients (*Rosen et al., 2005*).

*El-Mahallawy et al., (2002)* studied fungal infections in children with cancer at the National Cancer Institute in Cairo. They found that 68% of infections were caused by *Candida* sp. and 18% by *Aspergillus* sp.

Fungal infections pose a serious risk to immunocompromised patients. Over the past decade, a significant rise in the number of new infections has been observed in this population (*Groll et al., 1996*). Although *Candida* remains the most common fungal pathogen in

oncology patients, the epidemiology has recently shifted toward non-albicans species (*Moosa et al., 2002*).

This change has been attributed to the widespread use of fluconazole prophylaxis *Bodey et al., (2002)*; however, *Aspergillus* and uncommon molds have also seen a recent rise as pathogens identified in immunocompromised individuals (*Perea et al., 2002*).

The availability of newer therapeutic agents with improved efficacy, including immunomodulators, will be crucial in obtaining better control of infections due to fungal organisms (*Anaissie et al., 1998*; *Boogaerts et al., 2001*).